fostamatinib · Tavalisse
Small molecule
Evidence outlook
Approved: Immune Thrombocytopenia
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Also approved (4)
- Tavalisse (fostamatinib); licensee Knight Therapeutics
- Tavalisse tablets 100 mg and 150 mg for chronic idiopathic thrombocytopenic purpura (chronic ITP); holder Kissei
- Tavalisse for thrombocytopenia in adults with chronic ITP with insufficient response to other treatments
- Tavlesse: chronic immune thrombocytopenia (ITP) in adults refractory to other treatments; holder Instituto Grifols S.A.
Development in Rheumatoid Arthritis stopped as a strategic decision by the sponsor. Source
Development in Systemic Lupus Erythematosus stopped as a strategic decision by the sponsor. Source
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
FIT NCT02076399 · Immune Thrombocytopenia Registry: NCT02076399 | 3 | Number of Participants With Stable Platelet Response (Count of ≥50,000/µL on at Least 4 of the Last 6 Scheduled Visits Between Weeks 14 and 24) (From Week 14 to Week 24) 2016-04-21 | Number of Participants With Stable Platelet Response (Count of ≥50,000/µL on at Least 4 of the Last 6 Scheduled Visits Between Weeks 14 and 24) (From Week 14 to Week 24): Fostamatinib Recipient 9 Participants | Placebo Recipient 0 Participants | not yet graded | link ↗ |
View 1 more trial
FIT NCT02076412 · Immune Thrombocytopenia Registry: NCT02076412 | 3 | Number of Participants With Stable Platelet Response of at Least 50,000/µL (Baseline to Week 24) 2016-08 | Number of Participants With Stable Platelet Response of at Least 50,000/µL (Baseline to Week 24): Fostamatinib Recipient 9 Participants | Placebo Recipient 1 Participants | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (10)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (2)
What this study did
What this study did
Phase 2 (22)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (3)
What this study did
What this study did
What this study did
Phase 1 (22)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Immune Thrombocytopenia: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Fostamatinib (Tavalisse): this drug | Approved | Small molecule | Spleen tyrosine kinase (Syk) | not yet graded | No reviewed efficacy summary in this indication | |
| Rilzabrutinib | Approved | Small molecule | BTK | Reliable signal | No reviewed efficacy summary in this indication | |
| CID-103 | Phase 2 | Monoclonal antibody | CD38 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Tavalisse (fostamatinib) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.